Evidence map›Paper›PMID 34967268›Full record

ArticleDrug delivery2022

Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy.

Xue Liu, Zhenfeng Wu, Chunjing Guo, Huimin Guo, Yanguo Su, Qiang Chen, Changgang Sun, Qingming Liu, Daquan Chen, Hongjie Mu

Open access · goldAbstract read
In one paragraph

Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Pharmacodynamic Material Basis of the Components of FourJournal of hepatocellular carcinoma · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. [Multidimensional characteristics of the tumor microenviron-ment and advances in targeted delivery strategies].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Xue LiuCollaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai, PR China.
Zhenfeng WuKey Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, PR China.
Chunjing GuoCollege of Marine Life Science, Ocean University of China, Qingdao, PR China.
Huimin GuoCollaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai, PR China.
Yanguo SuCollaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai, PR China.
Qiang ChenCollaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai, PR China.
Changgang SunDepartment of Oncology, Weifang Traditional Chinese Hospital, Weifang, PR China.
Qingming LiuShandong Academy of Chinese Medicine, Jinan, PR China.
Daquan ChenCollaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai, PR China.ORCID 0000-0002-6796-0204
Hongjie MuCollaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs, School of Pharmacy, Yantai University, Yantai, PR China.
Yantai University · CNJiangxi University of Traditional Chinese Medicine · CNOcean University of China · CNShandong Academy of Chinese Medicine · CNWeifang Chinese Medicine Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the tumor hypoxic microenvironment and the new programmed cell death mode of combined ferroptosis, an angelica polysaccharide-based nanocarrier material was synthesized. The polymer contains hydrophilic angelica polysaccharide (ASP) that is linked by azobenzene (AZO) linker with ferrocene (Fc), and then the side chain was covalently modified with arachidonic acid (AA). It was postulated that the polymer micelles could work as an instinctive liver targeting drug delivery carrier, owing to the existence of ASP with liver targeting. Moreover, the aim was to engineer hypoxia-responsive polymer micelles which was modified by AA, for selective enhancement of ferroptosis in solid tumor, via diminishing glutathione (GSH) under hypoxia. Finally, we synthesized the amphiphilic polymer micelles AA/ASP-AZO-Fc (AAAF) by self-assembling. The structure of AAAF was confirmed by

Indexed as

AngelicaArachidonic AcidAzo CompoundsCell SurvivalChemistry, PharmaceuticalDrug CarriersDrug LiberationFerrous CompoundsHep G2 CellsHumansHydrophobic and Hydrophilic InteractionsHypoxiaLiver NeoplasmsMetallocenesMicellesNanoparticle Drug Delivery SystemArachidonic AcidazobenzeneAzo CompoundsDrug CarriersferroceneFerrous CompoundsMetallocenesMicellesNanoparticle Drug Delivery SystemPolysaccharidesangelica polysaccharideferroptosisHypoxia responsiveliver cancermicelle

Identifiers

PMID34967268
PMCPMC8725898
OpenAlexW4200179346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.